Tyche Wealth Partners LLC Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Tyche Wealth Partners LLC acquired a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,907 shares of the biotechnology company’s stock, valued at approximately $751,000.

Several other hedge funds have also recently modified their holdings of the stock. Capital International Investors lifted its stake in Axon Enterprise by 605.2% during the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock worth $366,449,000 after purchasing an additional 2,283,343 shares during the last quarter. Sands Capital Management LLC lifted its stake in Axon Enterprise by 101.6% during the second quarter. Sands Capital Management LLC now owns 1,993,126 shares of the biotechnology company’s stock worth $388,899,000 after purchasing an additional 1,004,556 shares during the last quarter. BlackRock Inc. increased its position in Axon Enterprise by 11.7% during the first quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company’s stock worth $1,872,883,000 after buying an additional 870,481 shares during the period. Norges Bank acquired a new position in Axon Enterprise during the fourth quarter worth approximately $102,920,000. Finally, Westfield Capital Management Co. LP increased its position in Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock worth $138,535,000 after buying an additional 451,350 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on AXON shares. StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Barclays upped their price objective on Axon Enterprise from $296.00 to $308.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. The Goldman Sachs Group upped their price objective on Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Robert W. Baird boosted their target price on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $312.64.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $1.01 on Wednesday, hitting $299.30. The company had a trading volume of 18,259 shares, compared to its average volume of 459,491. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. Axon Enterprise, Inc. has a 52-week low of $175.37 and a 52-week high of $329.87. The business has a 50 day moving average of $299.16 and a 200 day moving average of $256.71. The company has a market cap of $22.59 billion, a PE ratio of 130.57 and a beta of 0.93.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.29. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. The business had revenue of $432.14 million for the quarter, compared to the consensus estimate of $418.97 million. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 2.43 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.